Clinical significance of Janus Kinase inhibitor selectivity

• Published in: Rheumatology (Oxford, England) Vol. 58; no. 6; pp. 953 - 962
• Main Author: Choy, Ernest H
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.06.2019
• Subjects: Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Azetidines - therapeutic use; Humans; Inflammation - drug therapy; Janus Kinase Inhibitors - therapeutic use; Piperidines - therapeutic use; Pyrimidines - therapeutic use; Pyrroles - therapeutic use; Reviews; Sulfonamides - therapeutic use; targeted synthetic DMARDs; treatment; Janus Kinase; DMARDs; rheumatoid arthritis

Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: JAK1, JAK2, JAK3 and TYK2. Different cytokine rec...